Effectiveness of a new immuno-assay for the diagnosis of heparin-induced thrombocytopenia and improved specificity when detecting IgG antibodies

 

 Buy Article Permissions and Reprints

Summary

The diagnosis of heparin-induced thrombocytopenia (HIT) is based on clinical criteria and biological assays. Most immunoassays detect antibodies (either IgG alone or additionally IgA and IgM) against PF4 immobilised in wells of microtiter plates with stoichiometric concentrations of polyanion (heparin or polyvinylsulfonate). We studied whether diagnostic sensitivity and/or specificity for HIT could be improved using a novel assay in which unfractionated heparin is immobilised alone to the microwells, with PF4 (and, potentially, other heparin-dependent antigen proteins) provided by adding platelet lysate during the procedure. Samples from 101 patients with suspected HIT and from 101 controls (including 50 with antiphospholipid antibodies) were tested. The global assay (Zymutest HIA IgG/A/M^®, Hyphen BioMed) was positive for 39 of 40 patients with definite HIT (positive PF4-specific ELISA and positive serotonin release assay). It was positive in only two of the 101 control patients studied and also in 14 of the 61 patients with suspected HIT for whom the disease was excluded (specificity (sp): 77%). On the other hand, Zymutest HIA IgG^®, an IgG-specific assay, was positive in only six patients without HIT (Sp: 90%). Heparin-dependent IgG antibodies were present at higher levels in patients with definite HIT than in those for whom the diagnosis of HIT was ruled out. A single ELISA that detects IgG antibodies is more effective for the diagnosis of HIT in clinical practice. These results also support the hypothesis that heparin-dependent antibodies of IgG class have a major role in the pathogenesis of HIT.

• References

• 1 Chong BH. Heparin-induced thrombocytopenia. J Thromb Haemost 2003; 01: 1471-1478.
  CrossrefPubMedGoogle Scholar
• 2 Kelton JG, Warkentin TE. Heparin-induced thrombocytopenia: a historical perspective. Blood 2008; 112: 2607-2616.
  CrossrefPubMedGoogle Scholar
• 3 Warkentin TE, Sheppard JA, Moore JC. et al. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need?. J Lab Clin Med 2005; 146: 341-346.
  CrossrefPubMedGoogle Scholar
• 4 Greinacher A, Juhl D, Strobel U. et al. Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost 2007; 05: 1666-1673.
  CrossrefPubMedGoogle Scholar
• 5 Arepally G, Reynolds C, Tomaski A. et al. Comparison of PF4/heparin ELISA assay with the c-14-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 1995; 104: 648-654.
  CrossrefPubMedGoogle Scholar
• 6 Pouplard C, Amiral J, Borg JY. et al. Decision analysis for use of platelet aggregation test, carbon 14 serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 1999; 111: 700-706.
  CrossrefPubMedGoogle Scholar
• 7 Sheridan D, Carter C, Kelton J. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986; 67: 27-30.
  PubMedGoogle Scholar
• 8 Greinacher A, Michels I, Kiefel V. et al. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost 1991; 66: 734-736.
  Article in Thieme ConnectPubMedGoogle Scholar
• 9 Pouplard C, May MA, Iochmann S. et al. Antibodies to platelet factor 4 – Heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin – Clinical implications for heparin-induced thrombocytopenia. Circulation 1999; 99: 2530-2536.
  CrossrefPubMedGoogle Scholar
• 10 Juhl D, Eichler P, Lubenow N. et al. Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. Eur J Haematol 2006; 76: 420-426.
  CrossrefPubMedGoogle Scholar
• 11 Pouplard C, Amiral J, Borg JY. et al. Differences in specificity of heparin-dependent antibodies developed in heparin-induced thrombocytopenia and consequences on cross-reactivity with danaparoid sodium. Br J Haematol 1997; 99: 273-280.
  CrossrefPubMedGoogle Scholar
• 12 Warkentin TE, Greinacher A, Koster A. et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 340S-80S.
  CrossrefPubMedGoogle Scholar
• 13 Amiral J, Wolf M, Fischer AM. et al. Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Br J Haematol 1996; 92: 954-959.
  CrossrefPubMedGoogle Scholar
• 14 Lo GK, Sigouin CS, Warkentin TE. What is the potential for overdiagnosis of heparin-induced thrombocytopenia?. Am J Hematol 2007; 82: 1037-1043.
  CrossrefPubMedGoogle Scholar
• 15 Amiral J, Marfaing-Koka A, Wolf M. et al. Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia. Blood 1996; 88: 410-416.
  PubMedGoogle Scholar
• 16 Arnout J. The pathogenesis of the antiphospholipid syndrome: a hypothesis based on parallelisms with heparin-induced thrombocytopenia. Thromb Haemost 1996; 75: 536-541.
  Article in Thieme ConnectPubMedGoogle Scholar
• 17 Gruel Y. Antiphospholipid Syndrome and Heparin-induced Thrombocytopenia: Update on Similarities and Differences. J Autoimmun 2000; 15: 265-268.
  CrossrefPubMedGoogle Scholar
• 18 Gruel Y, Rupin A, Watier H. et al. Anticardiolipin antibodies in heparin-associated thrombocytopenia. Thromb Res 1992; 67: 601-606.
  CrossrefPubMedGoogle Scholar
• 19 Lasne D, Saffroy R, Bachelot C. et al. Tests for heparin-induced thrombocytopenia in primary antiphospholipid syndrome. Br J Haematol 1997; 97: 939.
  PubMedGoogle Scholar
• 20 Pauzner R, Greinacher A, Selleng K. et al. False-positive tests for heparin-induced thrombocytopenia in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Thromb Haemost 2009; 07: 1070-1074.
  CrossrefPubMedGoogle Scholar
• 21 Cognasse F, Boussoulade F, Chavarin P. et al. Release of potential immunomodulatory factors during platelet storage. Transfusion 2006; 46: 1184-1189.
  CrossrefPubMedGoogle Scholar
• 22 Zwicker JI, Uhl L, Huang WY. et al. Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost 2004; 02: 2133-2137.
  CrossrefPubMedGoogle Scholar
• 23 Warkentin TE, Sheppard JI, Moore JC. et al. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost 2008; 06: 1304-1312.
  CrossrefPubMedGoogle Scholar
• 24 Lo GK, Juhl D, Warkentin TE. et al. Evaluation of pretest clinical score (4 T‘s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006; 04: 759-765.
  CrossrefPubMedGoogle Scholar